Advocacy intelligence hub — real-time data for patient organizations
Emergent BioSolutions
Emergent BioSolutions
ABthraxTM: FDA approved
Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
ABthraxTM
Human Genome Sciences, Inc.
Raxibacumab
Emergent BioSolutions
ABthraxTM
(raxibacumab)Orphan drugHuman Genome Sciences, Inc.
Anthrax Protective Antigen-directed Antibody [EPC]
12.1 Mechanism of Action Raxibacumab is a monoclonal antibody that binds the protective antigen of B. anthracis [see Microbiology ( 12.4 )].
Anthim
(obiltoxaximab)Orphan drugstandardElusys Therapeutics, Inc.
Anthrax Protective Antigen-directed Antibody [EPC]
12.1 Mechanism of Action Obiltoxaximab is a monoclonal antibody that binds the PA of B. anthracis [see Microbiology ( 12.4 )] .
Alex King, MD
Covance
David Mathews, MD
Quintiles, Inc.
Jolene Berg, MD, M.D
Davita Clinical Research
📍 EDINA, MN
H. Frank Farmer, PhD, MD
Covance Research - Daytona Beach, Fl
Debra Mandarino, MD, md
Covance Research, Madison, WI
📍 MADISON, WI
Alan S Marion, MD, PhD
MDS Pharma Services